ArriVent's lung cancer drug falls short in Phase 3; cash runs to mid-2028

ArriVent BioPharma has told investors that its late-stage trial of firmonertinib in non-small cell lung cancer (NSCLC) failed to hit its main goal of delaying disease progression. The company disclosed the outcome on 9 November 2026, alongside its third-quarter results.

The top-line numbers show median time without progression of 11.0 months in one arm and 9.5 months in the other, a hazard ratio of 0.75. The information available does not say which arm produced which figure, and it gives no detail on the statistical analysis, so the size and robustness of the gap cannot yet be judged.

ArriVent has not announced any decision on the regulatory route for firmonertinib. It says it is working through the full dataset and expects to report back in the first quarter of 2027, which sets the earliest point at which the commercial outlook for the drug may become clearer.

The balance sheet gives the company some runway: it reported $393.2 million in cash, which it expects to fund operations until mid-2028. Other work continues. Recruitment is ongoing in the Phase 3 ALPACCA study in NSCLC with EGFR PACC mutations, and the first patient has begun treatment in an early-stage trial of ARR-002, an antibody-drug conjugate.